Hepcidin predicts response to IV iron therapy in patients admitted to the intensive care unit: a nested cohort study
| Autor: | Julie McMorrow, Craig French, Alisa Higgins, John K. Olynyk, Shannon Farmer, Joel P. A. Gummer, Bart De Keulenaer, Axel Hofmann, Wendy N. Erber, Robert D. Trengove, Janet Ferrier, Steve Webb, Toby Richards, David J Hawkins, Simon Towler, Stuart N. Baker, Edward Litton |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Anemia Hepcidin Anaemia Red blood cell transfusion 030204 cardiovascular system & hematology Critical Care and Intensive Care Medicine Placebo law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Intravenous iron law Internal medicine Medicine biology business.industry Research lcsh:Medical emergencies. Critical care. Intensive care. First aid 030208 emergency & critical care medicine lcsh:RC86-88.9 medicine.disease Intensive care unit Clinical trial Critical care Relative risk biology.protein business Cohort study |
| Zdroj: | Journal of Intensive Care, Vol 6, Iss 1, Pp 1-7 (2018) Journal of Intensive Care |
| ISSN: | 2052-0492 |
| Popis: | Background Both anaemia and red blood cell (RBC) transfusion are common and associated with adverse outcomes in patients admitted to the intensive care unit (ICU). The aim of this study was to determine whether serum hepcidin concentration, measured early after ICU admission in patients with anaemia, could identify a group in whom intravenous (IV) iron therapy decreased the subsequent RBC transfusion requirement. Methods We conducted a prospective observational study nested within a multicenter randomized controlled trial (RCT) of IV iron versus placebo. The study was conducted in the ICUs of four tertiary hospitals in Perth, Western Australia. Critically ill patients with haemoglobin (Hb) of |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |